Navigation Links
Pioneer Study Urges Caution Before Adopting ICER Reviews to Determine Cost Effectiveness of Treatments
Date:1/25/2019

Review methodology could negatively impact elderly, the disabled, cancer patients and those with rare diseases

As states continue to grapple with prescription drug costs, a new Pioneer Institute study lays out the key ethical, methodological and disease-specific questions policy makers should address before deciding whether to contract with the Institute for Clinical and Economic Review (ICER) to conduct cost effectiveness reviews used to make decisions about the purchase of medicines and other medical innovations.

ICER utilizes Quality Adjusted Life Years (QALYs), a controversial evaluation technique that assigns an economic value to the longevity and quality of human life.

“The use of the QALY standard in the United Kingdom resulted in British cancer patients having some of the worst access to new cancer treatments in all of Europe and created a political crisis for British politicians,” said William Smith, author of “Key Questions for Legislators on the Institute for Clinical and Economic Review (ICER).” “U.S. politicians may want to proceed cautiously in adopting QALYs.”

QALY is controversial because of the impact that such a methodology may have upon access to medical innovations for older Americans, the disabled, patients with cancer and patients with rare diseases.

The National Health Service (NHS) in the United Kingdom utilizes QALY metrics. But in the United States, the Affordable Care Act banned the use of QALYs for Medicare programs because of concerns about the impact upon older Americans, the disabled and the terminally ill.

Because of the vulnerability of these patient populations, Pioneer recommends that legislators avoid using ICER reviews until they are fully confident that the reviews will neither have an adverse impact upon these vulnerable populations nor discourage biopharmaceutical innovation for important unmet medical needs.

Download our one-page summary, “Key Questions for Legislators.”

About the Author

William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute. He has 25 years of experience in government and in corporate roles, including as vice president of public affairs and policy at Pfizer, and as a consultant to major pharmaceutical, biotechnology and medical device companies. He held senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Massachusetts Governor’s office. He is affiliated as research fellow and managing director with the Center for the Study of Statesmanship at The Catholic University of America (CUA), where he earned his PhD.

About Pioneer
Pioneer Institute is an independent, non-partisan, privately funded research organization that seeks to improve the quality of life in Massachusetts through civic discourse and intellectually rigorous, data-driven public policy solutions based on free market principles, individual liberty and responsibility, and the ideal of effective, limited and accountable government.

Read the full story at https://www.prweb.com/releases/pioneer_study_urges_caution_before_adopting_icer_reviews_to_determine_cost_effectiveness_of_treatments/prweb16056195.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Pioneers in Alzheimers research: Research couple honored for its lifetime achievement
2. 2 online science video pioneers combine to form new iBiology.org
3. Biometrics Pioneer DERMALOG Awarded German Foreign Trade Prize
4. Top 12 Pioneer Awards for seminal work in gene and cell therapy selected by blue ribbon panel
5. Pioneering path to electrical conductivity in tinker toy materials to appear in Science
6. David Allis, pioneer in epigenetics, to receive prestigious Japan Prize
7. Ronald Crystal, M.D., receives Pioneer Award
8. OU professor recognized by AAAS for pioneering efforts to advance ecological forecasting
9. Joseph Glorioso, Ph.D., receives Pioneer Award
10. Pioneer Award recipients Marina Cavazzana and Adrian Thrasher recognized for advancing gene therapy to the clinic for immunodeficiency disorders
11. Why didnt these pioneers of medicine receive a Nobel Prize?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2019)... ... ... Dr. Beanlands is the Vered Chair and Division Head of Cardiology at the ... of its National Cardiac PET Centre, and Professor in the University's Division of Cardiology ... of Cellular and Molecular medicine. , He is a founding member of ASNC, member ...
(Date:1/8/2019)... (PRWEB) , ... January 07, 2019 , ... Join industry ... Ridge for a live webinar on Thursday, January 17, 2019 at 1pm ... ongoing management of risk during the clinical trial process. Featured speakers will also present ...
(Date:1/7/2019)... ... January 07, 2019 , ... Concerto HealthAI, ... for precision health in oncology and other key therapeutic areas, and its Chief ... investors, entrepreneurs and executives spanning the entire healthcare landscape, on January 8, 2019, ...
Breaking Biology News(10 mins):
(Date:2/2/2019)... ... ... The top tech companies advancing artificial intelligence and data science are joining ... gathering of software engineers, data scientists and business executives. , Leaders in the ... Open Data Science Conference (ODSC) to demo software platforms at the event’s AI ...
(Date:2/2/2019)... ... February 01, 2019 , ... Biomatlante, ... appointment of its new CEO, Julien Dert, being effective on February 1st, 2019. ... in finance and management, in which more than 12 years in the Medical ...
(Date:1/30/2019)... ... January 29, 2019 , ... Mr. ... 2016. In his position as Director of Sales and Marketing, Mr. Schieving was ... across multiple industries the company supports. During this time, Mr. Schieving was responsible ...
(Date:1/30/2019)... Mass. (PRWEB) , ... January 29, 2019 , ... ... tell when someone is frustrated over something like a tricky math problem on ... research team led by Worcester Polytechnic Institute (WPI) computer science assistant professor ...
Breaking Biology Technology: